Syros Pharmaceuticals Inc.
SYRS - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$10.73K
Close$
$6.67
1668475% upside
Current Fair Value
1668475% upsideUndervalued by 1668475% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $10,733.00 |
|---|---|
| Enterprise Value | $-39,119,267.00 |
| Earnings per Share | $-5.81 |
| Beta | 1.36 |
| Outstanding Shares | 39,269,434 |
Return
| Return on Equity | 821.89% |
|---|---|
| Return on Assets | -107.56% |
| Return on Invested Capital | -197.03% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | -101.35 |
| Enterprise Value to EBIT | 0.35 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.49 |
| Debt to Equity | -1.72 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 2, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
March 31, 2027
EPS Estimate
$-4.38
Consensus analyst estimateRevenue Estimate
$4.49 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.00%▼ 1.18% |
|---|---|
| Total Invested | $3▼ 99.98% |
| Investors Holding | 1▼ 3.00% |
About Syros Pharmaceuticals Inc.
CEO: Nancy Simonian
